Like most Canadian cannabis companies listed on the Toronto Stock Exchange (TSX) and TSX Venture Exchange (TSX-V), Victoria-headquartered Emerald Health Therapeutics Inc. took a hit to its stock on October 17.
The company (TSX-V:EMH) suffered a 5% drop in stock value, as did many others. One cannabis company, Aphria Inc. (TSX:APH), took a 13% hit.
Investors were reacting to memos and staff notices put out the day before by the Canadian Securities Administrators, TMX Group (TSX:X) and Canadian Securities Exchange (CSE) that clarify the rules for publicly listed Canadian cannabis companies that have business interests in the U.S.
The TSX’s position was particularly chilling: any Canadian cannabis company on the TSX that does business in the U.S. and in any way “touches the flower” – has anything to do with the cultivation, distribution or possession of marijuana – could face delisting.
Nelson Bennett – Business In Vancouver – Oct. 30, 2017.
Want More Investigative Content?
